MX2019013537A - Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos. - Google Patents

Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos.

Info

Publication number
MX2019013537A
MX2019013537A MX2019013537A MX2019013537A MX2019013537A MX 2019013537 A MX2019013537 A MX 2019013537A MX 2019013537 A MX2019013537 A MX 2019013537A MX 2019013537 A MX2019013537 A MX 2019013537A MX 2019013537 A MX2019013537 A MX 2019013537A
Authority
MX
Mexico
Prior art keywords
compounds
diseases
prevention
treatment
aspects
Prior art date
Application number
MX2019013537A
Other languages
English (en)
Inventor
G Traber Peter
Zomer Eliezer
Shechter Sharon
Nir Raphael
M Johnson Joseph
George Ryan
Original Assignee
Galectin Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Sciences Llc filed Critical Galectin Sciences Llc
Publication of MX2019013537A publication Critical patent/MX2019013537A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H99/00—Subject matter not provided for in other groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Algunos aspectos de la invención se relacionan con compuestos sintéticos novedosos que tienen afinidad de enlace con las proteínas de galectina.
MX2019013537A 2017-05-12 2018-05-11 Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos. MX2019013537A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762505544P 2017-05-12 2017-05-12
PCT/US2018/032349 WO2018209255A1 (en) 2017-05-12 2018-05-11 Compounds for the prevention and treatment of diseases and the use thereof

Publications (1)

Publication Number Publication Date
MX2019013537A true MX2019013537A (es) 2020-02-13

Family

ID=64105444

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013537A MX2019013537A (es) 2017-05-12 2018-05-11 Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos.

Country Status (12)

Country Link
US (2) US11576924B2 (es)
EP (1) EP3621973A4 (es)
JP (1) JP7204676B2 (es)
KR (1) KR102626669B1 (es)
CN (1) CN110869378B (es)
AU (1) AU2018265571B2 (es)
BR (1) BR112019023722A2 (es)
CA (1) CA3062648A1 (es)
IL (1) IL270469B2 (es)
MX (1) MX2019013537A (es)
WO (1) WO2018209255A1 (es)
ZA (1) ZA201908165B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022511094A (ja) * 2018-12-06 2022-01-28 ブリストル－マイヤーズ スクイブ カンパニー ガレクチン－３の低分子阻害剤
KR20210143255A (ko) 2019-03-26 2021-11-26 브리스톨-마이어스 스큅 컴퍼니 갈렉틴-3의 소분자 억제제
US20220144818A1 (en) 2019-04-10 2022-05-12 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
US20220315619A1 (en) 2019-08-09 2022-10-06 Idorsia Pharmaceuticals Ltd (hetero)aryl-methyl-thio-beta-d-galactopyranoside derivatives
WO2021028570A1 (en) 2019-08-15 2021-02-18 Idorsia Pharmaceuticals Ltd 2-hydroxycycloalkane-1-carbamoyl derivatives
CN114585619A (zh) 2019-08-29 2022-06-03 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物
WO2021226002A1 (en) 2020-05-05 2021-11-11 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
CN115551850A (zh) 2020-05-11 2022-12-30 百时美施贵宝公司 半乳凝素-3的小分子抑制剂
EP4157833A1 (en) 2020-05-28 2023-04-05 Bristol-Myers Squibb Company Galectin-3 inhibitors
MX2023004033A (es) 2020-10-06 2023-04-27 Idorsia Pharmaceuticals Ltd Espiro derivados de alfa-d-galactopiranosidos.
KR20230104190A (ko) 2020-11-02 2023-07-07 이도르시아 파마슈티컬스 리미티드 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체
AU2022221092A1 (en) * 2021-02-09 2023-09-21 Idorsia Pharmaceuticals Ltd Hydroxyheterocycloalkane-carbamoyl derivatives
JP2024509421A (ja) 2021-03-03 2024-03-01 イドルシア・ファーマシューティカルズ・リミテッド トリアゾリル－メチル置換アルファ－ｄ－ガラクトピラノシド誘導体

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812681A1 (de) * 1988-04-16 1989-11-02 Bayer Ag Substituierte n-glycosylamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
GB9626450D0 (en) 1996-12-20 1997-02-05 Oxford Glycosciences Uk Ltd Therapeutic compounds
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
SE0401300D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
GB0501008D0 (en) * 2005-01-18 2005-02-23 Amura Therapeutics Ltd Method of producing conjugate vaccines
US9427449B2 (en) 2005-08-26 2016-08-30 Econugenics, Inc. Binding of galectin-3 by low molecular weight pectin
JP2010510223A (ja) 2006-11-15 2010-04-02 サ ブリガム アンド ウィメンズ ホスピタル インコーポレーティッド Ｔｉｍ−３調節物質の治療的使用
ES2543063T3 (es) 2008-05-16 2015-08-14 Galecto Biotech Ab Nueva síntesis de inhibidores de galactósidos
ES2652488T3 (es) 2009-04-28 2018-02-02 Galecto Biotech Ab Nuevos inhibidores de galactósidos de galectinas
EA201270316A1 (ru) 2009-08-25 2012-09-28 БиДжи МЕДИСИН, ИНК. Галектин-3 и сердечная ресинхронизирующая терапия
WO2011095772A2 (en) 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
CA2794066C (en) 2012-10-31 2017-02-28 Neil Henderson Galactoside inhibitor of galectins
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
ES2869884T3 (es) 2011-09-16 2021-10-26 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y la enfermedad de hígado graso no alcohólico
BR112014015940B1 (pt) 2011-12-28 2022-08-09 Galectin Therapeutics, Inc Polissacarídeo de grau farmacêutico, composição, e seus usos
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
CA2926917C (en) 2012-10-10 2021-01-05 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
ES2817888T3 (es) * 2012-10-31 2021-04-08 Galecto Biotech Ab Inhibidor de galactósido de galectina-3 y su uso para tratar fibrosis pulmonar
JP6366598B2 (ja) 2012-11-15 2018-08-01 タフツ ユニバーシティー ガレクチンタンパク質阻害剤を用いて被験体の眼の血管新生または繊維症を処置し、調節し、または、予防する方法、組成物、およびキット
KR20160122855A (ko) 2014-03-10 2016-10-24 라 졸라 파마슈티칼 컴파니 신장 질환 치료용 조성물 및 치료방법
US20170095496A1 (en) 2014-04-08 2017-04-06 Galecto Biotech Ab Galactoside inhibitors for new uses
WO2016005311A1 (en) 2014-07-09 2016-01-14 Galecto Biotech Ab Novel hybrid galactoside inhibitor of galectins
CA2970062C (en) * 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
US10799522B2 (en) 2015-07-27 2020-10-13 Wayne State University Compositions and methods relating to galectin detection
ES2921500T3 (es) 2015-11-09 2022-08-26 Galecto Biotech Ab 1,1'-sulfanodiil-di-beta-d-galactopiranósidos como inhibidores de galectinas
CN109071585B (zh) 2016-03-04 2022-08-16 卡莱克汀科学有限责任公司 预防和治疗半乳糖凝集素相关疾病的硒代半乳糖苷化合物及其用途
CA3062649A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof

Also Published As

Publication number Publication date
KR20200016246A (ko) 2020-02-14
WO2018209255A1 (en) 2018-11-15
EP3621973A1 (en) 2020-03-18
IL270469A (es) 2019-12-31
BR112019023722A2 (pt) 2020-05-26
JP7204676B2 (ja) 2023-01-16
IL270469B2 (en) 2023-07-01
JP2020519625A (ja) 2020-07-02
EP3621973A4 (en) 2021-10-27
US20230132265A1 (en) 2023-04-27
AU2018265571A1 (en) 2019-12-05
US20200155586A1 (en) 2020-05-21
KR102626669B1 (ko) 2024-01-17
CN110869378A (zh) 2020-03-06
CN110869378B (zh) 2023-10-13
IL270469B1 (en) 2023-03-01
ZA201908165B (en) 2023-07-26
AU2018265571B2 (en) 2022-09-29
CA3062648A1 (en) 2018-11-15
US11576924B2 (en) 2023-02-14

Similar Documents

Publication Publication Date Title
MX2019013537A (es) Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos.
JOP20220245A1 (ar) أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة
PH12017502180A1 (en) Tau-binding antibodies
MX365864B (es) Inhibidores de bromodominio biciclicos novedosos.
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
PH12017502207A1 (en) Tau-binding antibodies
MX2018010683A (es) Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos.
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
MX2015012428A (es) Tratamiento contra enfermedades mediadas th2 por inhibicion de bromodominios.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EA201891299A1 (ru) Терапевтические антитела к cd9
IL280664A (en) 2-Arylbenzimidazoles as PPARGC1A agonists for the treatment of neurodegenerative diseases
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
GB2567623B (en) Compression of 360 degree content
GB201804098D0 (en) Novel compounds and therapeutic uses thereof
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX2021004804A (es) Compuestos organolepticos novedosos.
MX2022000317A (es) Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5.
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations
WO2016135462A8 (en) Treatment
MX2018008731A (es) Compuestos organolepticos novedosos.
MX368075B (es) Compuestos organolepticos novedosos.